echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Arthritis Rheumatol: Incidence of COVID-19 in patients with rheumatic disease sedatiat ingested immunosuppressants

    Arthritis Rheumatol: Incidence of COVID-19 in patients with rheumatic disease sedatiat ingested immunosuppressants

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    The study was designed to describe the incidence and severity of 2019 coronavirus disease (COVID-19) in patients with rheumatoid diseases treated with synthetic or bio-anti-rheumatoid drugs (ts/bDMARDs) compared to the general population living in the same region of ItalyFrom 25 February 2020 to 10 April 2020, patients followed at the two tertiary rheumatism centres in Lombardy were invited to participate in a survey to identify confirmed patients with COVID-19, close contacts with known cases of COVID-19, infection symptoms, work, and changes in behaviour and disease treatment to prevent transmissionTHE INCIDENCE OF COVID-19 OF THE POPULATION OF LOMBARDY WAS OBTAINED FROM THE NATIONAL STATISTICAL OFFICECOVID-19 infection is determined by a nasopharyngeal swabA total of 955 patients (531 cases of rheumatoid arthritis, 203 cases of psoriasis, 181 cases of spinal arthritis and 40 cases of connective tissue disease/vascular inflammation/auto-inflammatory diseases; average age 53.7 years; women accounted for 67.4%)The response rate was 98.05 per centThe confirmed coVID-19 incidence was consistent with the general population (0.62% vs 0.66% ;p .92)No patients have serious complications or require intensive care, and all patients have temporarily suspended ongoing ts/bDMARDs treatmentAlmost all patients took preventive measures to prevent infection (90.6 per cent) and continued to use ts/bDMARDs (93.2%)89.5% of patients had stable disease activityAr's findings highlight the attitude of people with rheumatism to prevent infection while continuing chronic treatmentThe incidence and severity of COVID-19 in patients treated with ts/bDMARDs did not differ significantly from those in the general population in the same region
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.